Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
Medicine (Baltimore). 2023 Dec 29;102(52):e36621. doi: 10.1097/MD.0000000000036621.
Acquired factor VII (FVII) deficiency is a rare condition with various causes, including acquired inhibitors to FVII, liver disease, and malignancies. Myxoid pleomorphic liposarcoma is a rare and aggressive form of soft tissue sarcoma that can cause a range of clinical manifestations, including bleeding and clotting disorders.
We present a case report of a 21-year-old man with severe acquired FVII deficiency due to mediastinal myxoid pleomorphic liposarcoma. The patient presented with elevated International normalized ratio (INR) and a severe reduction in FVII coagulant activity, unresponsive to conventional therapy. While an acquired inhibitor to FVII was initially suspected, negative results from laboratory testing, including protein G sepharose adsorption and a Bethesda assay using Immunoglobulin G purified from patient plasma, made the diagnosis of an acquired inhibitor to FVII uncertain.
The patient underwent surgical resection of the tumor, supported by recombinant FVII infusion, leading to the normalization of coagulation parameters. However, a relapse of the disease was detected 6 months later when he was noted to have a decline in FVII levels.
This case highlights the importance of considering rare causes of bleeding and clotting disorders, particularly in unresponsive or atypical presentations. It also underscores the need for close monitoring and follow-up in patients with acquired FVII deficiency, even after successful treatment.
获得性因子 VII(FVII)缺乏症是一种罕见的病症,其病因包括获得性 FVII 抑制剂、肝脏疾病和恶性肿瘤等。黏液样多形性脂肪肉瘤是一种罕见且侵袭性较强的软组织肉瘤,可引起多种临床表现,包括出血和凝血障碍。
我们报告了一例 21 岁男性患者,因纵隔黏液样多形性脂肪肉瘤而患有严重获得性 FVII 缺乏症。该患者国际标准化比值(INR)升高,FVII 凝血活酶活性严重降低,对常规治疗无反应。尽管最初怀疑存在获得性 FVII 抑制剂,但实验室检测结果为阴性,包括蛋白 G 琼脂糖吸附和使用患者血浆中纯化的免疫球蛋白 G 进行的 Bethesda 测定,这使得获得性 FVII 抑制剂的诊断不确定。
患者接受了肿瘤切除术,同时给予重组 FVII 输注,凝血参数恢复正常。然而,6 个月后发现疾病复发,患者的 FVII 水平下降。
本病例强调了考虑罕见出血和凝血障碍原因的重要性,特别是在无反应或非典型表现时。它还强调了即使在成功治疗后,也需要对获得性 FVII 缺乏症患者进行密切监测和随访。